deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04527380

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Sponsor: Eli Lilly and Company

Conditions Enthesitis Related Arthritis Juvenile Psoriatic Arthritis
Interventions Adalimumab Ixekizumab
Updated 33 times since 2020 Last updated: May 16, 2025 Started: Apr 13, 2021 Primary completion: Feb 19, 2024 Completion: Apr 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04527380, this PHASE3 trial focuses on Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis and remains ongoing. Sponsored by Eli Lilly and Company, it has been updated 33 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Nov 2022 · 4 months · monthly snapshot~Nov 2022 – ~Mar 2023 · 4 months · monthly snapshot~Mar 2023 – ~Aug 2023 · 5 months · monthly snapshot~Aug 2023 – ~Oct 2023 · 2 months · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Jul 2025 · 5 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

33 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Jul 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 28 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  2. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE3

  4. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE3

  5. Nov 2023 — Feb 2024 [monthly]

    Recruiting PHASE3

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  7. Aug 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  8. Mar 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  9. Nov 2022 — Mar 2023 [monthly]

    Recruiting PHASE3

  10. Jul 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  11. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  12. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  13. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  14. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  15. Dec 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  16. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  17. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  18. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  19. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  20. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE3

  21. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE3

  22. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE3

  23. Feb 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE3

  24. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE3

  25. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

  26. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

  27. Oct 2020 — Nov 2020 [monthly]

    Not Yet Recruiting PHASE3

  28. Sep 2020 — Oct 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Basel, Switzerland , Berlin, Germany , Bremen, Germany , Brescia, Italy , Bristol, United Kingdom , Bron, France , Brussels, Belgium , Esplugues de Llobregat, Spain , Florence, Italy and 29 more locations